PATH | VRL
Menu

Immunogenicity of Live Attenuated Japanese Encephalitis SA 14-14-2 Vaccine Among Sri Lankan Children With Previous Receipt of Inactivated JE Vaccine

This article, published in Vaccine, describes the results of an open-label single arm safety and immunogenicity trial of live attenuated CD-JEV Japanese encephalitis (JE) vaccine among two- and five-year-old children in the Colombo District of Sri Lanka who had previously received two and three doses of inactivated mouse brain-derived JE vaccine (IMBV), respectively. The study found that administration of CD-JEV to these children with pre-existing neutralizing JE antibody titers was safe and resulted in substantial boosting of antibody levels. These results may inform other countries in Asia considering switching from IMBV to now World Health Organization-prequalified CD-JEV vaccine to combat this disease of public health importance.

Author: Wijesinghe PR, Abeysinghe MRN, Yoksan S, et al.

Published: 2016

» Visit web page (English)

(Located at www.sciencedirect.com)

Citation: Wijesinghe PR, Abeysinghe MRN, Yoksan S, et al. Immunogenicity of Live Attenuated Japanese Encephalitis SA 14-14-2 Vaccine Among Sri Lankan Children With Previous Receipt of Inactivated JE Vaccine. Vaccine. 2016;Early Online Publication.

Resource types: Peer-reviewed journal

Diseases/vaccines: Japanese encephalitis

Topics: Vaccine safety and performance, Disease/vaccine specific information

Regions: Asia